CD19/CD79B Bispecific CAR T Cells for Antigen Escape Resistance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for B cell malignancies, such as mantle cell lymphoma, face challenges due to antigen escape and high resistance to therapies, with CD19 CAR therapy showing treatment failures and a need for novel surface antigen targets.

Innovation Solution

Development of chimeric antigen receptors (CARs) that target both CD79b and CD19, incorporating specific binding domains and intracellular signaling components, for use in genetically modified T cells to enhance cancer treatment efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CD19 CAR therapy is used to treat B cell malignancies, then treatment efficacy is improved, but antigen escape and treatment resistance occur

Engineering Contradiction:

Improvetreatment efficacyVSAvoidantigen escape

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines CD19-binding domain and CD79b-binding domain into a single chimeric antigen receptor molecule. This bispecific CAR allows T cells to recognize and bind to both CD19 and CD79b simultaneously, preventing tumor cells from escaping therapy by downregulating or losing only one antigen. The merged receptor structure integrates two antigen specificities into one functional unit that mediates cytotoxic activity.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The chimeric antigen receptor is designed with multi-functionality by incorporating binding domains for both CD19 and CD79b antigens. This universal CAR can target multiple antigen types on the same tumor cell surface, making the therapy more versatile and reducing the likelihood of antigen escape. The receptor performs multiple functions: binding to CD19, binding to CD79b, and initiating T cell activation and cytotoxicity.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Adaptability or versatility

If novel surface antigen targets are developed to address antigen escape, then treatment versatility is improved, but CAR structure complexity increases

Engineering Contradiction:

Improvetargeting capabilityVSAvoidCAR structure

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The chimeric antigen receptor is constructed by segmenting different functional domains: an extracellular domain containing both CD19-binding and CD79b-binding regions, a transmembrane domain for cell membrane anchoring, and an intracellular signaling domain for T cell activation. This segmentation allows each domain to perform its specific function while maintaining overall receptor functionality. The modular structure facilitates the integration of multiple antigen specificities without excessive complexity.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS12600760B2Chimeric antigen receptors targeting CD79B and CD19

Publication Date: 2026.04.14 THE GENERAL HOSPITAL CORP

AI summary

Described herein are upfront methods for treating a patient suffering from a cancer. The method includes administering to the patient a therapeutically effective amount of an anti-cancer therapy including a chimeric antigen receptor (CAR) including an extracellular domain including a CD79b-binding domain and a CD19-binding domain, wherein the patient has not been previously treated for the cancer. The invention accordingly also relates to methods of producing and utilizing, e.g., T cells including CARs having an extracellular domain that binds CD79b and CD19.